Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

Completed · Phase 2

Conditions studied: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

In brief

RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with primary or secondary myelodysplastic syndromes.

Key facts

Study ID
NCT00072475
Run by
Alliance for Clinical Trials in Oncology
People needed
155
Starts
2003-12-01
Expected to finish
2014-06-01
Last updated by the study team
2016-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.